ALTHX.PA Theranexus SA

Healthcare Pharmaceuticals Euronext Paris
3.20 EUR
Close of Nov 7, 2026
1.49 4.75
Market cap
EUR 46.4M
P/E
-
P/B
15.58x
ROE
-13.5%
Dividend yield
-
Fundamental score
0.8/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALTHX.PA undervalued?

Graham number

The Graham number of Theranexus SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Theranexus SA fundamental analysis

3 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-72.86%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-52.87%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 1/2

The stock's PBV ratio (1.09x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

DER 1/2

The stock maintains a fair debt to equity ratio (85%), indicating a reasonable balance between the money it owes and the ownership it possesses.

Revenue Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Net Profit Growth 0/2

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Graham Number 1/1

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

Buffet Intrinsic Value 0/1

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Theranexus SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Theranexus SA

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pha…

Full company profile